ATE421883T1 - Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline - Google Patents

Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Info

Publication number
ATE421883T1
ATE421883T1 AT99969030T AT99969030T ATE421883T1 AT E421883 T1 ATE421883 T1 AT E421883T1 AT 99969030 T AT99969030 T AT 99969030T AT 99969030 T AT99969030 T AT 99969030T AT E421883 T1 ATE421883 T1 AT E421883T1
Authority
AT
Austria
Prior art keywords
glucan
compositions containing
specific immunoglobulins
containing beta
beta
Prior art date
Application number
AT99969030T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Fattom
Robert Naso
Original Assignee
Nabi Biopharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals filed Critical Nabi Biopharmaceuticals
Application granted granted Critical
Publication of ATE421883T1 publication Critical patent/ATE421883T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99969030T 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline ATE421883T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14

Publications (1)

Publication Number Publication Date
ATE421883T1 true ATE421883T1 (de) 2009-02-15

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99969030T ATE421883T1 (de) 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2002058711A1 (en) 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
EP1539194A4 (de) 2002-09-04 2007-06-13 Univ Louisville Res Found Krebstherapie mit beta-glucan und antikörpern
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
KR20070104590A (ko) * 2005-01-10 2007-10-26 나비 바이오파마슈티컬즈 스타필로코쿠스 아우레우스 감염을 치료하는 방법
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
EP1917019A2 (de) * 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung
MX2007013725A (es) * 2005-05-05 2008-04-09 Sensient Flavors Inc Produccion de beta-glucanos y mananos.
CN102698261A (zh) 2005-06-13 2012-10-03 葛兰素史密斯克蓝生物品公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1998802A2 (de) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
EP2719397A1 (de) 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Verwendung von Alpha-Toxin zur Behandlung und Prävention von Staphylococcus-Infektionen
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
CA3088918A1 (en) 2010-05-05 2011-11-10 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2684088T3 (es) 2011-06-19 2018-10-01 New York University Métodos de tratamiento y prevención de infecciones por staphylococcus aureus y afecciones asociadas
KR20140071318A (ko) 2011-06-19 2014-06-11 뉴욕 유니버시티 새로운 항-염증제 및 살균제로서의 류코톡신 e/d
EP2744517B1 (de) 2011-08-15 2019-03-13 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern gegen das staphylokokken-protein a
HK1207321A1 (en) 2012-04-26 2016-01-29 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
RU2643331C2 (ru) * 2012-04-30 2018-01-31 Байотера, Инк. Способы бета-глюкановой иммунотерапии
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3229833A1 (de) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Behandlungsverfahren
US11214600B2 (en) 2016-02-12 2022-01-04 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
EP3986555A4 (de) 2019-06-19 2023-06-28 The Research Foundation for The State University of New York Verfahren zur behandlung von neointimaler hyperplasie mit f11rl/jam-a-inhibitoren
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
IL291821A (en) 2019-10-02 2022-06-01 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use
US20250228908A1 (en) 2022-04-01 2025-07-17 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
WO2000015238A9 (en) 2000-10-12
CY1109437T1 (el) 2014-08-13
AU6033299A (en) 2000-04-03
ES2321892T3 (es) 2009-06-12
EP1121135B1 (de) 2009-01-28
CA2344166A1 (en) 2000-03-23
US6355625B1 (en) 2002-03-12
EP1121135A4 (de) 2005-03-16
EP1121135A1 (de) 2001-08-08
WO2000015238A1 (en) 2000-03-23
WO2000015238B1 (en) 2000-08-31
DK1121135T3 (da) 2009-03-23
DE69940371D1 (de) 2009-03-19
PT1121135E (pt) 2009-03-05
CA2344166C (en) 2008-11-18

Similar Documents

Publication Publication Date Title
ATE421883T1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
TR200000059T2 (tr) Piridin türevleri
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
NO965378L (no) Pyrazolo- og pyrrolopyridiner
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
DE60043868D1 (de) Abgeschwächte Mikroorganismen für die Behandlung von Infektionen
DE60033649D1 (de) Verbindungen und therapeutische methoden
ES2009140A6 (es) Un metodo de produccion de anticuerpos monoclonales humanos de proteccion cruzada y de composiciones que los contienen.
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
EA200100700A1 (ru) Гены и белки и их применение
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
EA200200704A1 (ru) Ослабленные микроорганизмы для лечения инфекции
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.
NO982151D0 (no) Hemoregulatoriske forbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1121135

Country of ref document: EP